OROSTICA TAPIA, KAREN YASMINE
Preferred name
OROSTICA TAPIA, KAREN YASMINE
Main Affiliation
ORCID
0000-0002-1403-3917
7 results
Now showing 1 - 7 of 7
- Some of the metrics are blocked by yourconsent settings
Item type:Product, Dataset - Integration of RNA Editing into Multiomics Machine Learning Models for Predicting Drug Responses in Breast Cancer Patients(GITHUB, 2026); ; 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Advances in machine learning for tumour classification in cancer of unknown primary: A mini-review(2025); Scopus© Citations 3 8 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A Comprehensive Analysis of the Effect of A>I(G) RNA-Editing Sites on Genotoxic Drug Response and Progression in Breast Cancer(2024); Dysregulated A>I(G) RNA editing, which is mainly catalyzed by ADAR1 and is a type of post-transcriptional modification, has been linked to cancer. A low response to therapy in breast cancer (BC) is a significant contributor to mortality. However, it remains unclear if there is an association between A>I(G) RNA-edited sites and sensitivity to genotoxic drugs. To address this issue, we employed a stringent bioinformatics approach to identify differentially RNA-edited sites (DESs) associated with low or high sensitivity (FDR 0.1, log2 fold change 2.5) according to the IC50 of PARP inhibitors, anthracyclines, and alkylating agents using WGS/RNA-seq data in BC cell lines. We then validated these findings in patients with basal subtype BC. These DESs are mainly located in non-coding regions, but a lesser proportion in coding regions showed predicted deleterious consequences. Notably, some of these DESs are previously reported as oncogenic variants, and in genes related to DNA damage repair, drug metabolism, gene regulation, the cell cycle, and immune response. In patients with BC, we uncovered DESs predominantly in immune response genes, and a subset with a significant association (log-rank test p < 0.05) between RNA editing level in LSR, SMPDL3B, HTRA4, and LL22NC03-80A10.6 genes, and progression-free survival. Our findings provide a landscape of RNA-edited sites that may be involved in drug response mechanisms, highlighting the value of A>I(G) RNA editing in clinical outcomes for BC.Scopus© Citations 4 7 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Integration of RNA Editing into Multiomics Machine Learning Models for Predicting Drug Responses in Breast Cancer Patients(MDPI AG, 2026-03-14); ; Background: The integration of multi-omics data, such as genomics and transcriptomics, into artificial intelligence models has advanced precision medicine. However, their clinical applicability remains limited due to model complexity. We integrated DNA mutation, RNA expression, and A>I(G) RNA editing data to develop a predictive model for drug response in breast cancer. Methods: We analyzed 104 patients from the Breast Cancer Genome-Guided Therapy Study (ClinicalTrials.gov: NCT02022202). Clinical variables, gene expression, tumor and germline DNA variants, and RNA editing features were integrated into machine learning models to predict therapy response. Generalized linear models (GLM), random forest (RF), and support vector machines (SVM) were trained and evaluated across multiple random 70/30 train-test splits. Feature selection was performed exclusively within the training set using LASSO regularization. Model performance was assessed using the F1-score on independent test sets. The additive effect of RNA editing was evaluated using paired comparisons across identical train/test splits. Results: We characterized the cohort using clinical, mutational, transcriptomic, and RNA editing profiles in 69 non-responders and 35 responders. Across repeated splits, adding RNA editing frequently maintained or modestly improved predictive performance, particularly in expression-based models, with paired analyses showing a statistically significant increase in F1-score. Conclusions: RNA editing represents a complementary molecular layer that can enhance multi-omic models for therapy response prediction in breast cancer, supporting further investigation of epitranscriptomic features in precision oncology.5 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers(2024); Scopus© Citations 5 13 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Scopus© Citations 11 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Disparities in mortality among HER2-positive breast cancer patients treated with trastuzumab in Chile (2015–2024): real-world evidence from 4,920 cases(Informa UK Limited, 2026-07-01);